J Korean Ophthalmol Soc.  2009 Aug;50(8):1184-1189. 10.3341/jkos.2009.50.8.1184.

Intravitreal Triamcinolone Versus Bevacizumab for Treatment of Diabetic Macular Edema

• Lee JW
• Lee BH
• Lim JH
• Lee KW

• KMID: 2212532
• DOI: http://doi.org/10.3341/jkos.2009.50.8.1184

Abstract

PURPOSE
To compare central macular thickness (CMT) and visual acuity outcomes after intravitreal injection of triamcinolone acetonide or bevacizumab for the treatment of diabetic macular edema (DME). METHODS: Fifty-one patients were randomly choosen to receive an intravitreal injection of either triamcinolone acetonide or bevacizumab. Patients were retrospectively reviewed, and 28 of 51 received an intravitreal injection of triamcinolone acetonide while the remaining 23 received bevacizumab injection. All patients underwent Snellen visual acuity testing, optical coherence tomography imaging and ophthalmoscopic examination at baseline and at four weeks following the injection. RESULTS: In the triamcinolone group, CMT decreased from 656.71+/-194.37 micrometer at baseline to 312.46+/-102.14 micrometer at the four-week follow-up visit, while in the bevacizumab group, CMT decreased from 582.17+/-151.02 micrometer at baseline to 453.09+/-172.39 micrometer at the follow-up (p<0.05). The LogMAR best-corrected visual acuity converted from the Snellen visual acuity significantly improved in the triamcinolone group (from 0.89+/-0.38 to 0.67+/-0.33) compared to the bevacizumab group (from 0.79+/-0.31 to 0.70+/-0.34) [p<0.05]. CONCLUSIONS: Intravitreal injection of triamcinolone may offer advantages over bevacizumab in the short-term management of DME, specifically with respect to improvement in CMT and visual acuity.

Keyword

Bevacizumab; Diabetic macular edema; Triamcinolone

MeSH Terms

Antibodies, Monoclonal, Humanized
Follow-Up Studies
Humans
Intravitreal Injections
Macular Edema
Retrospective Studies
Tomography, Optical Coherence
Triamcinolone
Triamcinolone Acetonide
Visual Acuity
Bevacizumab
Antibodies, Monoclonal, Humanized
Triamcinolone
Triamcinolone Acetonide

Reference

References

1. Ryan SJ. Etiologic mechanisms in diabetic retinopathy. Retina. 4th ed.2. St. Louis, Missouri: Mosby;2006. p. 1241–70.

2. Klein R, Klein BE, Moss SE. Visual impairment in diabetes. Ophthalmology. 1984; 91:1–9.

3. Early treatment diabetic retinopathy study report number 1. Photocoagulation for diabetic macular edema. Arch Ophthalmol. 1985; 103:1796–805.

4. Bresnick GH. Diabetic maculopathy: a critical review highlighting diffuse macular edema. Ophthalmology. 1983; 1301–17.

5. Jonas JB, Sofker A. Intraocular injection of crystalline cortisone as adjunctive treatment of diabetic macular edema. Am J Ophthalmol. 2001; 132:425–7.

6. Audren F, Lecleire-Collet A, Erginay A, et al. Intravitreal triamcinolone acetonide for diffuse diabetic macular edema: phase 2 trial comparing 4 mg vs 2 mg. Am J Ophthalmol. 2006; 142:794–9.

7. Martidis A, Duker J, Greenberg PB, et al. Intravitreal triamcinolone for refractory diabetic macular edema. Ophthalmology. 2002; 109:920–7.

8. Jonas JB. Intravitreal triamcinolone acetonide for diabetic retinopathy. Dev Ophthalmol. 2007; 39:96–110.

9. Massin P, Audren F, Haouchine B, et al. Intravitreal triamcinolone acetonide for diabetic diffuse macular edema: preliminary results of a prospective controlled trial. Ophthalmology. 2004; 111:218–24.

10. Sutter FK, Simpson JM, Gillies MC. Intravitreal triamcinolone for diabetic macular edema that persists after laser treatment. Ophthalmology. 2004; 111:2044–9.

11. Bonini-Filho MA, Jorge R, Barbosa JC, et al. Intravitreal injection versus subtenon's infusion of triamcinolone acetonide for refractory diabetic macular edema: a randomized clinical trial. Invest Ophthalmol Vis Sci. 2005; 46:3845–9.

12. Karacorlu M, Ozdemir H, Karacorlu S, et al. Intravitreal triamcinolone as a primary therapy in diabetic macular oedema. Eye. 2005; 19:382–6.

13. Haritoglou C, Kook D, Neubauer A, et al. Intravitreal bevacizumab (avastin) therapy for persistent diffuse diabetic macular edema. Retina. 2006; 26:999–1005.

14. Arevalo JF, Fromow-Guerra J, Quiroz-Mercado H, et al. Primary intravitreal bevacizumab (avastin) for diabetic macular edema: results from the Pan-american collaborative retina study group at 6-month follow-up. Ophthalmology. 2007; 114:743–50.

15. Cunningham ET Jr, Adamis AP, Altaweel M, et al. A phase II randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema. Ophthalmology. 2005; 112:1747–57.

16. Chun DW, Heier JS, Topping TM, et al. Pilot study of multiple intravitreal injections of ranibizumab in patients with center− involving clinically significant diabetic macular edema. Ophthalmology. 2006; 113:1707–12.

17. Umland SP, Nahrebne DK, Razac S, et al. The inhibitory effects of topically active glucocorticoids on IL-4, IL-5, and interferon− gamma production by cultured primary CD4 T cells. J Allergy Clin Immunol. 1997; 100:511–9.

18. Floman N, Zor U. Mechanism of steroid action in ocular inflammation: inhibition of prostoglandin production. Invest Ophthalmol Vis Sci. 1977; 16:69–73.

19. Bandi N, Kompella UB. Budesonide reduces vascular endothelial growth factor secretion and expression in airway(Calu-1) and alveolar (A549) epithelial cells. Eur J Pharmacol. 2001; 425:109–16.

20. Wilson CA, Berkowitz BA, Sato Y, et al. Treatment with intravitreal steroid reduces blood-retinal barrier breakdown due to retinal photocoagulation. Arch Ophthalmol. 1992; 110:1155–9.

21. Costa RA, Jorge R, Calucci D, et al. Intravitreal bevacizumab for choroidal neovascularization caused by AMD (IBeNA Study): Results of a phase 1 dose-escalation study. Invest Ophthalmol Vis Sci. 2006; 47:4569–78.

22. Costa RA, Jorge R, Calucci D, et al. Intravitreal bevacizumab (avastin) for central and hemicentral retinal vein occlusions: IBeVO study. Retina. 2007; 27:141–9.

23. Rosenfeld PJ, Fung AE, Puliafito CA. Optical coherence tomography findings after an intravitreal injection of bevacizumab (avastin) for macular oedema from central retinal vein occlusion. Ophthalmic Surg Lasers Imaging. 2005; 36:336–9.

24. Paccola L, Costa RA, Folgosa MS, et al. Intravitreal triamcinolone versus bevacizumab for treatment of refractory diabetic macular edema (IBEME study). Br J Ophthalmol. 2008; 92:76–80.

25. Cho HY, Lee JH. The correlation visual acuity and paterns of diabetic macular edema in OCT images. J Korean Ophthalmol Soc. 2003; 44:2028–34.

26. Kim YG, Yu SY, Kwak HW. The effect of intravitreal triamcinolone acetonide injection according to the diabetic macular edema type. 2005; 46:84–9.

27. Shimura M, Nakazawa T, Yasuda K, et al. Comparative evaluation of intravitreal bevacizumab and triamcinolone acetonide on persistent diffuse diabetic macular edema. Am J Ophthalmol. 2008; 145:854–61.

28. Kim SJ, Equi R, Bressler NM. Analysis of macular edema after cataract surgery in patients with diabetes using optical coherence tomography. Ophthalmology. 2007; 114:881–9.

29. Beer PM, Bakri SJ, Singh RJ, et al. Intraocular concentration and pharmacokinetics of triamcinolone acetonide after a single intravitreal injection. Am J Ophthalmol. 2003; 110:681–6.

30. Bakri SJ, Snyder MR, Reid JM, et al. Pharmacokinetics of intravitreal bevacizumab (avastin). Ophthalmology. 2007; 114:855–9.